Pediatric Neurology Resident King Faisal Specialist Hospital and Research Centre, Saudi Arabia
Rationale: To review the efficacy of clobazam in Dravet syndrome.
Methods: Retrospective cohort study review of patient with Dravet syndrome who were treated with Clobazam. The following information will be collected age, gender, weight, seizure type, frequency, pre and post, Clobazam dose, discontinuation, side effect, details of concomitant AED regimens.
Results: We have a total of 25 patients, five of them are girls, and 120 are boys. Nineteen (76%) of them showed improvement on clobazam in different semiology, 9 (591.6%) of patients with Myoclonic, 9 (64.2%) with tonic clonic and 3(75%) with absence. But four (28.5%) patients of them with Tonic Clonic semiology showed no improvement. Five patients became seizure free in rang dose 0.4 mg/kg to 1.3 mg/kg. Two out of 14 (14.2%) with Tonic clonic became seizure free with clobazam at dose 1.3 mg/kg, two out of 12 (16.6%) with myoclonic became seizure free with 0.4 mg/kg to 0.9 mg/kg. One out of 3 (33%) with tonic posture became free of seizure with clobazam at 0.9 mg/kg. Two patients with tonic clonic was on Levetiracetam and when we add clobazam they became seizure free. Two patient with myoclonic was on Levetiracetam, Topamax, Valproic Acid they became seizure free. One patient with tonic was on Levetiracetams and when we add clobazam he became seizure free. There are three (12%) patients who developed side effect in form of sedition, and only one patient had his dose adjusted. There was no difference in patient age of starting clobazam or sex.
Conclusions: Clobazam showed significant improvement in 76% of the patient with Dravet syndrome. And only 12% showed side effect. Age and sex did not affect the outcome of clobazam.
Funding: Please list any funding that was received in support of this abstract.: KFSHRC